Synageva BioPharma’s SBC-102 Gets US FDA Orphan Drug Status to Treat Lysosomal Acid Lipase Deficiency

Synageva BioPharma’s SBC-102 gets US FDA orphan drug status to treat lysosomal acid lipase deficiency
Synageva BioPharma Corp, a privately held biopharmaceutical company, announced that the US Food and Drug Administration (FDA) has granted orphan drug designation for SBC-102, the company’s enzyme replacement therapy in development to treat Lysosomal Acid Lipase (LAL) Deficiency, also known as Wolman Disease and Cholesteryl Ester Storage Disease (CESD), a condition for which there is currently no …
Read more on PharmaBiz

Study confirms that methadone works and saves lives for injecting drug users
Research carried out by the universities of Bristol, Cambridge and Edinburgh found that opiate substitution treatment reduced the frequency of drug use and led to a drop in the risk of death by 13 per cent each year.
Read more on PhysOrg